Clearmind Medicine (CMND) - 2023 Q3 - Quarterly Report

(iii) On February 14, 2022, the Company completed a share purchase agreement with Medigus, whereby the Company issued a total of 66,244 units to Medigus in consideration for US$750,000 ("Cash Financing") and 27,778 common shares of Medigus ("Share Exchange"). Each unit is comprised of one common share and one warrant, with each warrant exercisable for a period of 18 months at CAD$60.00 per share. In addition, Medigus will be entitled to 10% of the initial equity of a potential venture in the area of psyched ...